Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-1002 gene therapy in NYHA Class III non-ischemic cardiomyopathy
NCT05598333Phase 2Active, not recruiting
- Sponsor
- AskBio
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 12
01
Overview
A Phase 2 trial of umiposgene parvec in heart failure (HF), sponsored by AskBio. Started Oct 2023; status: active, not recruiting.
02
Drugs
umiposgene parvec
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05598333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05598333.